GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » cbdMD Inc (AMEX:YCBD) » Definitions » Debt-to-EBITDA

cbdMD (YCBD) Debt-to-EBITDA : 0.97 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is cbdMD Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

cbdMD's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $1.15 Mil. cbdMD's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $2.96 Mil. cbdMD's annualized EBITDA for the quarter that ended in Jun. 2024 was $4.23 Mil. cbdMD's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 0.97.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for cbdMD's Debt-to-EBITDA or its related term are showing as below:

YCBD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.33   Med: -0.4   Max: -0.22
Current: -1.33

During the past 9 years, the highest Debt-to-EBITDA Ratio of cbdMD was -0.22. The lowest was -1.33. And the median was -0.40.

YCBD's Debt-to-EBITDA is ranked worse than
100% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs YCBD: -1.33

cbdMD Debt-to-EBITDA Historical Data

The historical data trend for cbdMD's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

cbdMD Debt-to-EBITDA Chart

cbdMD Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only - -0.55 -0.28 -0.34 -0.58

cbdMD Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.99 -0.73 -1.71 -0.60 0.97

Competitive Comparison of cbdMD's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, cbdMD's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


cbdMD's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, cbdMD's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where cbdMD's Debt-to-EBITDA falls into.



cbdMD Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

cbdMD's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.28 + 2.403) / -6.341
=-0.58

cbdMD's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.15 + 2.959) / 4.232
=0.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.


cbdMD  (AMEX:YCBD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


cbdMD Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of cbdMD's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


cbdMD Business Description

Traded in Other Exchanges
Address
8845 Red Oak Boulevard, Charlotte, NC, USA, 28217
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD and hempMD. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD bath bombs, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
Executives
Thomas Ronan Kennedy officer: Interim CEO and CFO 8845 RED OAK BLVD, CHARLOTTE NC 28217
Bakari T. Sellers director 4231 VOORHEES ROAD, DENMARK SC 29042
Raines William F Iii director 8314 TOSOMOCK LANE, HUNTERSVILLE NC 28078
Scott G. Stephen director 4249 NORTH WINCHESTER AVE., CHICAGO IL 60613
Sibyl Nichole Swift director 730 HAWTHORNE LANE, APT 441, CHARLOTTE NC 28204
Kevin Macdermott officer: President 9580 CALDWELL RD, MOUNT ULLA NC 28125
Wiesehan John J Iii officer: Chief Revenue Officer 8845 RED OAK BOULEVARD, CHARLOTTE NC 28217
Sim Farar director 8845 RED OAK BOULEVARD, CHARLOTTE NC 28217
Martin A. Sumichrast director, officer: Chairman of the Board and CEO 11125 COLONIAL COUNTRY LANE, CHARLOTTE NC 28277
Raymond Scott Coffman director 230 S. TRYON ST., #1302, CHARLOTTE NC 28202
Peter J. Ghiloni director 115 DEER ESTATES LANE, PONTE VEDRA BEACH FL 32082
Mark S Elliott officer: CFO & COO C/O LEVEL BRANDS, INC., 4521 SHARON ROAD, SUITE 450, CHARLOTTE NC 28211
Gregory C Morris director 421 CRANBORNE CHASE, FORT MILL SC 29708
Caryn Nicole Dunayer officer: President 8476 CATAWBA DOVE DR., BELMONT NC 28012
Erik Sterling 10 percent owner 5505 KALANIANAOLE HWY, HONOLULU HI 96821

cbdMD Headlines

From GuruFocus

cbdMD Inc Extraordinary Shareholders Meeting Transcript

By GuruFocus Research 02-15-2024

cbdMD Stock Appears To Be Modestly Undervalued

By GF Value GF Value 05-16-2021

Q3 2021 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

cbdMD Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-15-2024

cbdMD Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-15-2024

Q2 2021 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q1 2022 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q1 2024 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2024 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 05-16-2024